Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHENZHEN STOCK EXCHANGE  >  Huadong Medicine Co., Ltd.    000963   CNE0000011S1

HUADONG MEDICINE CO., LTD.

(000963)
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Huadong Medicine : China Anti-Obesity Prescription Drugs Market Research Report 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/17/2019 | 12:29pm EDT

The China Anti-Obesity Prescription Drugs market is valued at USD 55.20 million in 2018 and is expected to reach USD 72.53 million by the end of 2025, growing at a CAGR of 3.90% between 2019 and 2025.

This report studies the Anti-Obesity Prescription Drugs development status and future trend in China, focuses on top players in China, also splits Anti-Obesity Prescription Drugs by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The China Anti-Obesity Prescription Drugs market is valued at USD 55.20 million in 2018 and is expected to reach USD 72.53 million by the end of 2025, growing at a CAGR of 3.90% between 2019 and 2025.

Browse the report at - https://www.crystalmarketreport.com/china-anti-obesity-prescription-drugs-market-research-report-2018/

The major players in global market include -

Zhejiang Hisun

ZHIEN pharmaceutica

Lunan

Wanhan

Huadong Medicine

Roche

Other

Geographically, this report splits the China market into seven regions -

South China

East China

Southwest China

Northeast China

North China

Central China

Northwest China

Read full details of Table of contents - https://www.crystalmarketreport.com/china-anti-obesity-prescription-drugs-market-research-report-2018/toc

On the basis of product, the Anti-Obesity Prescription Drugs market is primarily split into -

OTC

Rx

On the basis on the end users/applications, this report covers -

Hospitals Pharmacies

Retail Pharmacies

E-commerce

Request free sample - https://www.crystalmarketreport.com/sample/211028

Table of Contents:

1 Anti-Obesity Prescription Drugs Overview 1

2 China Anti-Obesity Prescription Drugs Market Competition by Players/Manufacturers 22

3 China Anti-Obesity Prescription Drugs Sales and Revenue by Regions (2014-2019) 32

4 China Anti-Obesity Prescription Drugs Sales and Revenue by Type/ Product Category (2014-2019) 37

5 China Anti-Obesity Prescription Drugs Sales by Application (2014-2019) 42

6 Analysis of Anti-Obesity Prescription Drugs Industry Key Manufacturers 45

6.1 Zhejiang Hisun 45

6.2 ZHIEN pharmaceutica 47

6.3 Lunan 49

6.4 Wanhan 51

6.5 Huadong Medicine 53

6.6 Roche 55

7 Anti-Obesity Prescription Drugs Manufacturing Cost Analysis 57

8 Industrial Chain, Sourcing Strategy and Downstream Buyers 63

9 Marketing Strategy Analysis, Distributors/Traders 66

10 Factors Influencing 73

10.1 Price Trend of Key Industrial Raw Material 73

10.2 Imports & Exports 74

11 China Anti-Obesity Prescription Drugs Market Size (Sales and Revenue) Forecast (2020-2025) 80

12 Research Findings and Conclusion 86

13 Methodology and Data Source 87

Read full details of Table of contents - https://www.crystalmarketreport.com/china-anti-obesity-prescription-drugs-market-research-report-2018/toc

About Us:

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 200,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Media Contact

Company Name: Crystal Market Reports

Contact Person: Tom Sam

Email: sales@crystalmarketreport.com

Phone: 1-518-730-0564

Address:90 State Street, Suite 700

City: Albany

State: New York 12207

Country: United States

Website: www.crystalmarketreport.com/china-anti-obesity-prescription-drugs-market-research-report-2018

Source: www.abnewswire.com

.

(C) 2019 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
HUADONG MEDICINE CO., LTD. End-of-day quote.
ROCHE HOLDING AG 0.83% 289.8 Delayed Quote.20.13%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HUADONG MEDICINE CO., LTD.
09/17HUADONG MEDICINE : China Anti-Obesity Prescription Drugs Market Research Report ..
AQ
2018HUADONG MEDICINE : Sinclair Pharma agrees to potential offer from China's Huadon..
RE
2018HUADONG MEDICINE : Sinclair Pharma says Chinese firms given more time to make ta..
RE
2018HUADONG MEDICINE : Britain's Sinclair Pharma gets takeover interest from Chinese..
RE
More news
Financials (CNY)
Sales 2019 35 056 M
EBIT 2019 3 601 M
Net income 2019 2 803 M
Finance 2019 2 008 M
Yield 2019 2,13%
P/E ratio 2019 15,8x
P/E ratio 2020 13,3x
EV / Sales2019 1,24x
EV / Sales2020 1,08x
Capitalization 45 495 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 36,76  CNY
Last Close Price 26,00  CNY
Spread / Highest target 69,6%
Spread / Average Target 41,4%
Spread / Lowest Target -3,85%
EPS Revisions
Managers
NameTitle
Liang Lü General Manager & Director
Bang Liang Li Chairman
Xin Hua Bai Chairman-Supervisory Board
Hong Lan Ma Chief Financial Officer
Cheng Wei Liu Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HUADONG MEDICINE CO., LTD.6 424
JOHNSON & JOHNSON1.29%350 587
ROCHE HOLDING AG19.25%248 542
MERCK AND COMPANY11.29%217 734
PFIZER-16.38%201 883
NOVARTIS16.20%198 243